Stocktwits on MSN9d
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same Page
Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...
Shelbyville man accused of sexually assaulting child
James Eddy Risinger, 78, was arrested on Tuesday. According to Shelby County Sheriff Kevin Windham, he has been charged with ...
Eli Lilly climbs after earnings, top analyst talks what's next for pharma giant
Rep. Ro Khanna (D-Calif.) joins 'Squawk Box' to discuss President Trump's third week back in office, DOGE and Elon Musk's efforts to downsize the federal government, working across the aisle in the ...
Leerink maintains Tectonic stock Outperform with $69 target
Leerink Partners analyst David Risinger noted the significant concern about the likelihood of success of TX45 in PH-HFpEF following the termination of Eli Lilly (NYSE:LLY)'s study. However, the firm ...
Vertex Pharmaceuticals: Strong Buy Rating Driven by Suzetrigine Approval and Promising Market Prospects
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...
Hosted on MSN1mon
Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here’s why
Wall Street’s forecasts were missed across the board. Despite this setback, Leerink Partners analyst David Risinger maintained his positive outlook on Eli Lilly, citing promising developments in ...
Buy Rating for Bristol-Myers Squibb Driven by Cobenfy’s Strong Sales Momentum and Growth Potential
Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...
Investor's Business Daily on MSN6mon
AnaptysBio Surges After Sanofi Takes A Stake In $100 Million Offering
Notably, Sanofi's corporate arm — rather than its venture capital business — reached out to invest in AnaptysBio, Leerink ...